Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 9/20 | 0.51 |
| ▸ | CTSB | P07858 | 8/20 | 0.51 |
| ▸ | CTSS | P25774 | 8/20 | 0.51 |
| ▸ | CTSK | P43235 | 6/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5513786 | 1.00 | CTSL (0.51) | CTSLCTSBCTSSCTSKNAAA | |
| SCHEMBL5516421 | 0.80 | NAAA (0.43) | NAAA | |
| SCHEMBL3898239 | 0.70 | CTSL (0.57) | CTSLCTSBCTSSCTSK | |
| SCHEMBL5508656 | 0.70 | CTSK (0.58) | CTSLCTSBCTSSCTSK | |
| SCHEMBL5518535 | 0.70 | CTSK (0.58) | CTSLCTSBCTSSCTSK | |
| SCHEMBL5512829 | 0.70 | CTSK (0.58) | CTSLCTSBCTSSCTSK | |
| SCHEMBL5512832 | 0.70 | CTSK (0.58) | CTSLCTSBCTSSCTSK | |
| SCHEMBL2156304 | 0.70 | CTSK (0.66) | CTSLCTSBCTSSCTSK | |
| SCHEMBL27647527 | 0.68 | CTSL (0.57) | CTSLCTSBCTSSCTSK | |
| SCHEMBL2156068 | 0.67 | CTSK (0.66) | CTSLCTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122268-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2006-06-08 | — | — | US | claimed |
| EP-1537074-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2005-06-08 | — | — | EP | claimed |
| WO-2004022526-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2004-03-18 | — | — | WO | claimed |
| US-7279478-B2 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA & CO. (CA) | 2007-10-09 | — | — | US | disclosed |
| US-20060122268-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2006-06-08 | — | — | US | disclosed |
| EP-1537074-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004022526-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122268-A1 | Cathepsin cysteine protease inhibitors | CTSB, CTSS, CTSK | CTSL 8/4885CTSB 1/4885CTSS 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.